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Over the last two decades, carotid artery stenting (CAS) has established itself as an alternative to ca-rotid endarterectomy (CEA) in the treatment of 
carotid stenoses in patients at high risk for surgery.1-5 Anoth-
er step in the improvement of CAS was managed by demon-
strating reduced cerebral embolic event rates with the use 
of cerebral embolic protection systems within large carotid 
stent registries. 6-8 However, despite the use of distal filter 
devices, the occurrence of cerebral embolic events could be 
documented.9,10 Brain imaging studies and the use of tran-
scranial Doppler investigations could show lower silent ce-
rebral embolic event rates within endarterectomy compared 
with CAS despite the use of filter devices.11,12 The occur-
rence of cerebral embolic events despite the use of distal 
filter devices may be related to different weaknesses of this 
type of protection device. A large proportion of emboli is 
<80 µm in size,13,14 but the pore size of most available filter 
devices is >80 µm. Besides, due to the rigidity of many filter 
devices, and a required minimal distal landing zone depend-
ing on the length of the basket of the filter device, the vessel 
wall apposition (especially in tortuous vessel segments) may 
not be optimal and could therefore allow cerebral emboli-
zation.15,16 Nevertheless, randomized controlled trials com-
paring CEA and CAS mandating for embolic protection 
were able to demonstrate the equivalence of both proce-
dures with regard to the occurrence of stroke.17,18 These trials 
were performed using rather old filter devices. The newly 
designed Gore embolic filter (Gore Medical) incorporates a 
diamond-shaped frame that optimizes vessel wall apposition 
and minimizes the required distal landing zone. This might 
be advantageous in tortuous vessels with small landing zones 
and severe kinking. Besides, this filter was designed to be 
used in carotid artery interventions as well as in coronary 
and peripheral interventions. Herewith, we report the first 
clinical experiences with the use of the Gore embolic filter 
in the context of CAS. 
 
Methods
We used the Gore embolic filter for distal embolic pro-
tection device in patients undergoing CAS of the proximal 
internal carotid artery (ICA) or carotid bifurcation with a 
symptomatic stenosis of ≥50% or asymptomatic stenosis of 
≥70% (according to NASCET criteria).19 Symptomatic status 
was defined as carotid artery stenosis associated with ipsilat-
eral transient ischemic attack (TIA), amaurosis fugax, isch-
emic stroke, or retinal infarction within 6 months prior to 
enrollment.
Baseline examinations prior to the procedure consisted 
of a physical examination as well as documentation of the 
relevant medical history including cardiovascular risk factors, 
past cardiovascular and neurological events, current symp-
toms of concomitant cardiovascular disease, medication, and 
patient demographic information. Furthermore, we con-
ducted routine laboratory tests (including cardiac enzymes) 
and a 12-lead electrocardiogram. We performed either col-
or-coded duplex ultrasound, magnetic resonance angiogra-
phy, or selective angiography for preprocedure assessment of 
the extracranial vessels.
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Patients received 100 mg aspirin and 75 mg clopidogrel, 
starting at least 3 days before the procedure. Alternatively, 
loading doses of 500 mg aspirin and 300 mg clopidogrel 
were administered the day before the procedure. At the be-
ginning of the intervention, unfractionated heparin (5000-
10,000 IU) was administered to achieve an activated clotting 
time (ACT) of at least 250 seconds. At 2-3 minutes before 
stent dilation, 1 mg of atropine was administered to prevent a 
vasovagal reaction due to stimulation of the baroreceptors in 
the area of the carotid bulb. Post procedure, all patients were 
on 100 mg aspirin daily indefinitely and 75 mg clopidogrel 
daily for a minimum of 30 days.
Prior to the procedure and before discharge, certified 
physicians carried out a neurological assessment consisting 
of a complete examination using the NIH (National Insti-
tute of Health) stroke scale. In cases of suspected neurologi-
cal events (TIA, minor or major strokes), cranial imaging was 
performed and a neurologist was consulted. 
The procedures were performed under local anesthesia 
applied in the area of vascular access. Baseline angiography 
of the ipsilateral side included at least two projections to 
determine the grade of stenosis according to the NASCET 
criteria,19 and thus, to confirm subject eligibility. Further-
more, we performed an angiography of the ipsilateral intra-
cerebral circulation immediately before and after the carotid 
intervention. Patient heart rates and blood pressures were 
monitored continuously throughout the procedure. In addi-
tion to continuous heart rate, electrocardiogram, and blood 
pressure monitoring, periodic neurologic assessments were 
performed during every critical step of the procedure. 
The Gore embolic filter system consists of three parts: 
the embolic filter device, a delivery catheter, and a retrieval 
catheter. The filter is available in two sizes: a 5 mm filter 
diameter for a reference vessel diameter from 2.5-4.0 mm, 
and a 7 mm filter diameter for a reference vessel diameter 
from 4.0-5.5 mm. The system is compatible with guide cath-
eters and sheaths with a minimum inner diameter of 0.066˝. 
The embolic filter device itself consists of two parts (Figure 
1), a proximal nitinol frame formed out of six alveolar cells 
and a filter basket made of polytetrafluoroethylene (ePTFE). 
The proximal frame consists of a nitinol wire forming six 
diamond-shaped circles that are disposed adjacent to each 
other to form a ring. This ring is 9 mm long when using the 
5 mm-diameter version of the filter and 11 mm long when 
using the 7 mm-diameter version. It allows an optimized cir-
cumferential vessel wall apposition. The filter basket has a hy-
drophilic heparin coating and is perforated with pores with a 
nominal pore size of 100 µm. The proximal end of the frame 
is attached to a 0.014˝ PTFE-coated guidewire, and its distal 
tip passes through the distal end of the filter basket with a 
shapeable, radiopaque floppy tip. The guidewire rotates free-
ly and is independent of the filter position. The device has 
four radiopaque markers: three located on the frame and one 
on the radiopaque collar, which connects the guidewire to 
the filter. The guidewire is lightly supportive to be able to 
cross most lesions. In very calcified lesions, it might be ad-
vantageous to use an even lighter supportive wire. Therefore, 
the guidewire is available in a 185 cm-long rapid-exchange 
configuration and a 300 cm-long over-the-wire configura-
tion. Both the delivery catheter and retrieval catheter have 
a working length of 150 cm. The delivery catheter has an 
outer diameter of 3.2 Fr, while the outer diameter of the re-
trieval catheter is 4.8 Fr and contains a radiopaque marker at 
its distal tip. The delivery catheter with the guidewire inside 
is advanced through the lesion. The position is appropriate 
when the most proximal radiopaque marker of the frame 
is past the lesion, with adequate room for the tip of the 
stent delivery system. Next, maintaining the wire position 
while carefully pulling back the delivery catheter deploys 
FIGURE 1. Schematic representation of the Gore embolic filter 
with labeling of the most important components.
FIGURE 2. Angiographic picture of the deployed Gore embolic fil-
ter with labeling of the most important components.
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the filter. The device deployment is completed when the 
three radiopaque markers on the nitinol frame are separate, 
indicating the frame is released from the delivery catheter 
and apposing the vessel wall (Figure 2). Once the filter is 
positioned, CAS can be performed using any commercially 
available carotid stent. If excessive debris is collected in the 
filter and blood flow is obstructed, aspiration of blood prox-
imal to the device is indicated prior to retrieval of the filter. 
During advancement of the retrieval catheter, the position 
of the guidewire must be maintained carefully. The retrieval 
catheter is advanced over the wire to the radiopaque collar 
under fluoroscopic guidance. Further advancement of the 
retrieval catheter will lead the frame of the embolic filter to 
collapse within the catheter. Retrieval of the device is com-
pleted when the radiopaque frame markers come together 
to form a single marker and subsequently overlap with the 
radiopaque marker on the tip of the retrieval catheter. This 
means that only the proximal frame of the filter is collapsed 
within the catheter, while the distal filter bag protrudes out 
of the catheter. If the decision is made to retrieve the filter 
completely into the retrieval catheter, this may lead to tear-
ing of the filter bag or rupture and release of embolic debris. 
Finally, the entire system must be pulled slowly through the 
guiding catheter under fluoroscopic guidance.
We analyzed our patients for the appearance of any ma-
jor adverse event (TIA, stroke, myocardial infarction, or death) 
within 30 days after carotid intervention. TIA was defined as 
an acute neurological deficit lasting <24 hours, with or with-
out evidence of a new ischemic brain infarct upon brain imag-
ing. The criteria for stroke were new neurological deficits with 
new ischemic or hemorrhagic defects detected on computed 
tomography or magnetic resonance imaging. In addition, we 
evaluated all procedures in regard to technical success, which was 
achieved when the Gore embolic filter was delivered, placed, 
and retrieved without causing any acute adverse event. 
If patients were not available for clinical 30-day follow-up, 
they were contacted by telephone. We documented the car-
diovascular history and the patient’s medication. In cases of 
new neurological symptoms, a neurological assessment was 
required and/or office reports were ordered.
The first 9 filters used within this case series were placed 
in formalin after the interventions and sent to Gore Medi-
cal’s Products Division in Flagstaff, Arizona for analysis. The 
filters were tested for structural integrity and the debris cap-
tured within the filter bags was histologically analyzed.
Statistical analysis. Statistical analysis was performed 
on an intention-to-treat principle. Nominal and categorical 
Table 1. Baseline characteristics.
Characteristic n = 20
Male gender 12 (60%)
Age (years) 72.2 ± 8.5
Symptomatic status
   Asymptomatic 13 (65%)
   Symptomatic 7 (35%)
   Recurrent events 4 (20%)
Concomitant disease
   Peripheral arterial occlusive disease 6 (30%)
   Prior neck dissection 1 (5%)
   Coronary artery disease 10 (50%)
   Hypertension 14 (70%)
   Diabetes 4 (20%)
   Hyperlipidemia 9 (45%)
   Smoking 3 (15%)
High-risk criteria
   Anatomical 1 (5%)
   Clinical 6 (30%)
   Both 1 (5%)
Angiographic baseline characteristics
   Contralateral ICA stenosis 4 (20%)
   Percentage stenosis
       Range
74.2 ± 9.1 
55.1-95.3
Data provided as mean ± standard deviation or number (percentage). 
ICA = internal carotid artery.
Table 2. Results.
Results n = 20
Procedure duration
   Procedure time (min) 56.4 ± 15.9
   Radiation time (min) 11.9 ± 6.8
   Filter time (min) 11.4 ± 6.1
Predilation 2 (10%)
Stent systems 20 (100%)
   Protege 11 (55%)
   Precise 3 (15%)
   Wallstent 4 (20%)
   Xact 2 (10%)
Primary endpoint 1 (5%)
   Periprocedural 0 (0%)
   Until discharge 0 (0%)
   At 30-day follow-up 1 (5%)
Secondary endpoint
   Technical success 20 (100%)
Histological analysis 9 (45%)
   Structural integrity of the filter 9/9 (100%)
   Acute clot material associated with the device 0/9 (0%)
   Inflammatory tissue/debris 8/9 (88.9%)
Data provided as mean ± standard deviation or number (percentage).
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variables are displayed as frequencies and percentages. Values 
for continuous variables are expressed as means ± standard 
deviation. All data were analyzed using BiAS for Windows 
(version 10.04).
 
Results
We included 20 patients in this first single-center expe-
rience on the use of the Gore embolic filter in carotid in-
terventions. Mean patient age was 72.2 ± 8.5 years, and 12 
patients (60%) were male. Seven patients (35%) had a symp-
tomatic stenosis. Of these, 4 patients had a history of >1 
neurological event (including amaurosis fugax, TIA, or isch-
emic stroke); 1 patient had 2 episodes of TIA at 18 months 
and 5 months prior to stent implantation. One patient had 
2 episodes of amaurosis fugax; the last event was 2 months 
before the intervention. Two patients suffered both a stroke 
and an amaurosis fugax within 6 months prior to the proce-
dure. Patient baseline characteristics are outlined in Table 1. 
Eight patients were considered at high risk for carotid sur-
gery. Anatomical high-risk criteria were present in 2 patients 
(10%). Both had a history of neck dissection. Seven patients 
(35%) met clinical high-risk criteria, as they were older than 
75 years. Of those, both anatomical and clinical risk factors 
were present in 1 patient, as he was 77 years old and had a 
history of neck surgery. On angiography, the mean diameter 
of stenosis was 74.2 ± 9.1%.
Technical success was achieved in all 20 patients. Mean 
procedure time was 56.4 ± 15.9 minutes with an average 
radiation time of 11.9 ± 6.8 minutes. The average filter time 
from deployment until retrieval of the Gore embolic filter 
was 12.1 ± 7.1 minutes. In 1 patient, the Gore embolic fil-
ter was used as a second embolic protection system. In this 
particular case, we first decided to use the Gore flow-reversal 
system (Gore Medical), but after insertion of the balloon 
sheath into the common carotid artery and placement of 
the balloon wire in the external carotid artery, test injection 
of contrast medium showed that even after several place-
ment attempts flow reversal failed and consequently cerebral 
protection was not established. Therefore, we advanced the 
embolic filter over the balloon sheath of the flow-reversal 
device and crossed the target lesion in the ICA.
Predilation before stent placement was performed in 2 
patients (10%). The remaining 18 patients underwent direct 
stent implantation. A stent was implanted in all 20 patients. 
We chose an open-cell stent design in 14 patients (70%) and 
a closed-cell stent design in 6 patients (30%). Hybrid stents 
were not used within this study. The distribution of implant-
ed stent systems is shown in Table 2.
Histological analysis of the filters used in the first 9 pa-
tients demonstrated structural integrity of all devices and did 
not reveal any acute clot material related to the device. Be-
yond that, debris was detected in 8 out of 9 analyzed filters. 
The debris was primarily composed of necrotic tissue, min-
eralization, and intact and degenerated inflammatory nuclei. 
All aforementioned components were considered common 
for the degenerative disease process of atherosclerosis and 
consequently considered to be shed embolic tissue.
Major adverse events (TIA, stroke, myocardial infarction, 
or death) within 30 days after stent implantation occurred in 
1 patient. An 83-year-old woman with an asymptomatic ste-
nosis of the left ICA who was treated with direct stent im-
plantation of a 9 x 30 mm Protégé stent (ev3 Endovascular, 
Inc) had a TIA with a paresis of the right arm 21 days after 
the intervention. She was admitted to a local stroke unit. Ce-
rebral computed tomography scan at the time of hospital ad-
mission could prove no new ischemic lesion, and the deficits 
dissolved completely within 24 hours from symptom onset.
In all patients, the Gore embolic filter was used suc-
cessfully as the cerebral embolic protection device during 
CAS without the appearance of a neurological complication 
within the procedure or until discharge. 
In 3 procedures, there were minor, non-relevant technical 
difficulties that did not influence the functionality of the 
device. In 2 of these cases, friction occurred during deploy-
ment of the device; however, this did not result in movement 
of the wire or the filter in the distal landing zone. Even after 
removal of the device, no damage or bending of the wire 
could be detected. In 1 case, the retrieval catheter was caught 
in the proximal stent struts. Rotating the patient’s head to 
reorient the anatomy and performing a second postdilation 
thereafter enabled removal of the retrieval catheter. 
Discussion
The initial results using the Gore embolic filter show 
great promise for an effective and safe new embolic protec-
tion device in carotid interventions. Within our case series, 
we saw no relevant technical complications using the device, 
and no acute periprocedural embolism resulting in neuro-
logical disorders occurred. There was only 1 TIA within 30 
days of follow-up. No patient suffered a stroke or died. These 
are the first results in the routine use of the Gore embolic 
filter as embolic protection system during CAS, and they are 
favorable when compared with those of the interventional 
arms of large randomized trials comparing CAS vs CEA. 
The stroke and death rate after 30 days was 6.8% in the 
interventional group of the SPACE trial4 and 9.6% in the 
EVA-3S study. 5 Even in the CREST trial, in which distal fil-
ters were used without exception, 4.4% of the patients ran-
domized to stent implantation had a stroke or died through 
30 days of follow-up. 17
While the Gore embolic filter was specifically designed 
to avoid the common weaknesses of distal filter devices, one 
disadvantage remains: crossing of the target lesion by the de-
vice is required before cerebral protection can be established. 
A possible advantage in design and handling of the system 
is that rotational freedom between the guidewire and the 
filter components is enabled. When the device is loaded and 
deployed, the guidewire is free to rotate independently of 
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the filter. This allows a more stable placement of the filter in 
its deployed state in the landing zone, as periprocedural ma-
nipulation of the wire is not directly transferred to the filter. 
In cases with complex anatomy (eg, severe tortuosity), this 
technical specificity may lead to better wall apposition of the 
system. The idea of wire movement independent of the filter 
itself is not unique to the Gore embolic filter; for example, 
it is implemented in the Emboshield NAV6 (Abbott Vas-
cular) as well. However, this feature alone is not enough to 
ensure optimal wall apposition; the diamond-shaped frame 
also helps to ensure a circumferential apposition to the vessel 
wall. In contrast, the proximal end of the NAV6 is rather 
round, increasing the risk of inadequate wall apposition in 
more oval vessels. This results in an increased risk of peripro-
cedural embolization. In vitro tests comparing the Gore em-
bolic filter with the NAV6 showed significantly increased 
filter efficacy with the Gore device (P<.001).20
Another potential drawback of most distal filter devices 
is their pore size. Studies using cerebral imaging or peripro-
cedural transcranial Doppler examination demonstrated a 
higher rate of silent ischemic embolism despite the use of 
cerebral protection devices.21-25 This is mainly due to the 
pore sizes of the filters limiting their protective effect. How-
ever, particle sizes smaller than the pore sizes have shown 
to lead to significant cerebral embolism.13-15 The Gore Em-
bolic Filter has a distal filter bag pore size of 100 µm, and 
therefore has the second smallest pore size of all currently 
commercially available distal protection devices.26,27 With its 
three-dimensional fiber network, only the FiberNet device 
(Medtronic, Inc) generates a smaller pore size of 40 µm.28 
It should be noted, however, that the smaller the pore size 
of a device, the larger the increase of longitudinal vascular 
impedance.29 An in-vitro performance assessment comparing 
five distal filter devices with different pore sizes could not 
show significantly different volume flow rates between the 
devices. When filled with debris, an increase in vascular re-
sistance and a decrease in the volume flow rate could be de-
tected for all devices; however, there was no correlation be-
tween pore size and changed flow condition.27 A small pore 
size is associated with an increased risk of functional closure 
of the filter by collecting even small particles of debris. This 
requires permanent periprocedural monitoring by the inter-
ventionalist and may necessitate the intermittent aspiration 
of debris. Therefore, we could see cases with functional filter 
occlusion due to high filter efficiency when using the Fiber-
net device (pore size, 40 µm) that required blood aspiration 
before continuation of the procedure.28
Müller-Hülsbeck et al used in-vitro benchtop models to 
prove that the efficacy of debris capture of distal filter de-
vices is highly dependent on the tortuosity of the target ves-
sel.30-33 They tested four different distal filter devices for filter 
efficacy as a function of vessel tortuosity. The results showed 
considerable differences between the tested devices. While the 
amount of non-captured debris increased non-significantly in 
severe tortuosity compared with normal anatomy when using 
the FilterWire EX (Boston Scientific), a significant decrease 
of filter efficacy (P<.001) was detected when using the An-
gioguard RX (Cordis Endovascular) in tortuous vessels. The 
Gore embolic filter was designed to allow optimal wall ap-
position even when positioned in tortuous vessels. Its unique 
configuration results in a required landing zone, which is only 
slightly longer than the proximal frame itself. This may be an 
additional advantage when used in tortuous vessels. In vitro 
tests by Siewiorek et al compared six distal filter devices for 
embolic protection and found that the Gore embolic filter 
had the highest capture efficiency of all participating devices 
with relatively small increase in pressure gradient and vascular 
impedance after injection of the debris-simulating particles 
(143 µm, 99.97%; 200 µm,100%).20  
Study limitations. This report reflects our initial experi-
ence with the Gore embolic filter and discussed accordingly 
only a small sample size. All procedures were performed by 
a single operator with vast experience in the field of CAS. 
Therefore, our results may not be completely transferred 
to other centers. Furthermore, we did not perform routine 
postprocedure brain diffusion-weighted magnetic resonance 
imaging/computed tomography in order to detect small and 
mainly asymptomatic defects caused by the small emboli ca-
pable of passing through the pores of the filter.
Conclusion
These initial results of the use of the novel Gore embolic 
filter satisfy safety and performance criteria for the treat-
ment of carotid artery stenosis. With its specific properties, 
the system seems to have the potential to compensate at least 
some of the classic disadvantages of distal filters for embolic 
protection. Further investigation and evaluation are justified 
and needed. 
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